Suven Life Sciences Ltd has secured one product patent each from Eurasia, Japan and one from Mexico for its New Chemical Entities (NCEs).
The granted claims of the patents include the class of selective 5-HT compounds discovered by the Hyderabad-based company and were being developed as therapeutic agents.
"`They are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention Deficient Hyperactivity Disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia,’’ Suven said in a release issued here on Tuesday.
With these new patents, Suven has 13 patents from Eurasia, 12 from Japan and 17 from Mexico.